Fundic gland polyp Medical Services in China

Fundic gland polyp (FGP) is the most common type of gastric polyp, typically arising from the fundus and body of the stomach. These are benign, non-neoplastic lesions composed of dilated, cystically enlarged fundic glands lined by parietal and chief cells—without dysplasia in the vast majority of sporadic cases. FGPs are usually discovered incidentally during upper gastrointestinal endoscopy performed for unrelated indications such as dyspepsia, reflux, or anemia. Pathogenetically, sporadic FGPs are strongly associated with long-term proton pump inhibitor (PPI) use, likely due to PPI-induced hypergastrinemia leading to fundic gland hyperplasia. In contrast, FGPs occurring in the context of familial adenomatous polyposis (FAP) are genetically driven (APC gene mutations) and carry a higher, albeit still low, risk of dysplasia—particularly when larger (>1 cm), numerous (>20), or histologically atypical. Epidemiologically, FGPs are found in approximately 0.8–2.5% of routine upper endoscopies in Western populations and up to 5–8% in patients on chronic PPI therapy; they are more prevalent in middle-aged and older adults (peak incidence 50–70 years), with a slight female predominance. Risk factors include prolonged PPI use (>1 year), age >50, female sex, and—critically—undiagnosed or untreated FAP. While most FGPs are asymptomatic and do not impair quality of life directly, their incidental discovery often triggers patient anxiety about cancer risk, unnecessary repeat endoscopies, and healthcare overutilization. Larger or multiple polyps may rarely cause nonspecific symptoms such as epigastric discomfort or occult gastrointestinal bleeding, but these are uncommon. Importantly, FGPs themselves do not cause functional gastric impairment, nor do they alter digestion or nutrient absorption. However, persistent concern about malignancy, repeated surveillance endoscopies, and potential overtreatment can negatively affect psychological well-being and daily functioning—especially among health-anxious individuals. Management focuses on accurate diagnosis (via high-definition endoscopy with targeted biopsy), risk stratification (sporadic vs. FAP-associated), and judicious surveillance rather than routine resection. Current guidelines (e.g., ACG, ESGE) recommend no removal for typical small (<1 cm), isolated, histologically confirmed sporadic FGPs, reserving endoscopic resection for lesions with suspicious features (size ≥1 cm, irregular surface, ulceration, or dysplasia on biopsy) or in confirmed FAP patients. Patient education regarding the overwhelmingly benign nature of sporadic FGPs—and the importance of evaluating for underlying FAP in young patients or those with multiple polyps—is essential to alleviate distress and optimize long-term outcomes.

Fundic gland polyps (FGPs) are the most common gastric polyps in Western populations, typically identified incidentally during upper endoscopy. They arise from hyperplasia and cystic dilation of the fundic glands—specifically the parietal and chief cells—in the gastric fundus and body. FGPs are almost exclusively benign, with negligible malignant potential in sporadic cases; however, their clinical significance lies in their association with underlying conditions and potential implications for surveillance strategies.

The primary cause of sporadic FGPs is chronic, long-standing proton pump inhibitor (PPI) use. Prolonged acid suppression leads to hypergastrinemia, which stimulates fundic gland proliferation via gastrin’s trophic effects on enterochromaffin-like (ECL) cells and gastric epithelial progenitors. This results in architectural distortion, glandular cystic dilation, and eventual polyp formation. The risk increases with duration and dose of PPI therapy, particularly after >1–2 years of continuous use. Discontinuation of PPIs may lead to regression in some cases, supporting a direct pharmacologic causality.

A second major etiologic pathway involves germline APC gene mutations, as seen in familial adenomatous polyposis (FAP). In FAP-associated FGPs, polyps are typically more numerous (>100), larger, and may exhibit dysplastic changes—including low-grade or high-grade intraepithelial neoplasia—conferring increased neoplastic risk. These polyps arise due to constitutive Wnt/β-catenin pathway activation secondary to APC loss, driving aberrant epithelial proliferation independent of gastrin. Importantly, FGPs in FAP patients often precede colonic polyposis and may serve as an early endoscopic clue to undiagnosed hereditary disease.

Genetic factors beyond APC include rare variants in MUTYH (associated with MUTYH-associated polyposis), though FGPs are less characteristic in this syndrome. No strong associations exist with Lynch syndrome or other common hereditary gastrointestinal cancer syndromes. Genome-wide association studies have not identified common low-penetrance susceptibility alleles for sporadic FGPs, suggesting that genetic predisposition—outside of monogenic disorders—is minimal.

Environmental and modifiable risk factors include chronic atrophic gastritis (particularly autoimmune gastritis), although this association is less robust than with PPI use or FAP. Autoimmune gastritis induces achlorhydria and compensatory hypergastrinemia, potentially contributing to fundic gland hyperplasia. However, FGPs are distinctly uncommon in Helicobacter pylori–positive atrophic gastritis, where intestinal metaplasia and oxyntic gland atrophy predominate; in fact, H. pylori infection appears protective against FGP development, likely by preserving acid secretion and limiting gastrin elevation. Smoking has not been consistently linked to FGPs, and alcohol consumption shows no established association. Dietary factors—including high salt, nitrate, or processed meat intake—have not demonstrated reproducible correlations with FGP incidence.

Demographic and clinical risk factors include female sex (2:1 female-to-male predominance), older age (peak incidence 50–70 years), and Caucasian ethnicity. Obesity and metabolic syndrome show weak or inconsistent associations in epidemiologic studies. Concurrent use of other acid-suppressive agents (e.g., histamine-2 receptor antagonists) carries substantially lower risk compared to PPIs, likely due to less profound and sustained acid inhibition. Notably, FGPs are exceedingly rare in children and adolescents, reinforcing the role of cumulative environmental exposures over time.

Importantly, FGPs must be distinguished histopathologically from other gastric polyps—especially hyperplastic polyps (often antral, associated with chronic gastritis and H. pylori) and adenomas (dysplastic, often in the antrum or preneoplastic in FAP). Endoscopic features—including location (fundus/body), size (<1 cm typical), smooth surface, and translucent appearance—support diagnosis but require biopsy confirmation. While sporadic FGPs rarely progress to malignancy, surveillance is recommended in FAP patients due to documented dysplasia risk and potential for gastric adenocarcinoma. In contrast, isolated sporadic FGPs <1 cm without dysplasia generally do not warrant routine surveillance unless new polyps emerge or clinical context changes (e.g., initiation of long-term PPI therapy in a high-risk patient). Understanding these multifactorial causes and risk stratifications enables evidence-based endoscopic management and appropriate genetic counseling when indicated.

Fundic gland polyps (FGPs) are the most common gastric polyps encountered in clinical practice, typically arising from the fundus and body of the stomach. They are composed of dilated, cystically transformed fundic glands lined by parietal and chief cells, and are almost invariably benign. FGPs are strongly associated with chronic proton pump inhibitor (PPI) use and, less commonly, with familial adenomatous polyposis (FAP). Importantly, they are asymptomatic in the vast majority of cases—often discovered incidentally during upper gastrointestinal endoscopy performed for unrelated indications such as dyspepsia, gastroesophageal reflux disease (GERD), or iron-deficiency anemia. Consequently, there are no characteristic early or typical symptoms attributable to FGPs themselves.

Early symptoms: Fundic gland polyps do not produce early warning signs. Patients rarely experience any symptom directly caused by the polyps—even when multiple or large (>1 cm)—in the absence of coexisting pathology. Any early complaints reported by patients (e.g., mild epigastric discomfort, bloating, or intermittent nausea) are nonspecific and more likely attributable to underlying functional dyspepsia, chronic gastritis, GERD, or PPI-induced hypergastrinemia rather than the polyps per se. Notably, serum gastrin levels may be elevated in long-term PPI users, but this biochemical change is asymptomatic and does not correlate with polyp burden or symptomatology.

Typical symptoms: There are no typical symptoms of FGPs. The overwhelming majority of patients remain entirely asymptomatic throughout the natural history of these lesions. When symptoms are present, they reflect comorbid conditions—not the polyps. For example, a patient undergoing endoscopy for chronic heartburn may be found to have numerous small FGPs, but the heartburn stems from esophageal acid exposure, not gastric mucosal protrusions. Similarly, patients with FAP-associated FGPs may report colonic symptoms (e.g., rectal bleeding, diarrhea, or change in bowel habits), but these arise from colorectal adenomas or carcinoma—not gastric polyps.

Accompanying symptoms: FGPs may coexist with other gastric pathologies that do generate symptoms. These include chronic atrophic gastritis (potentially causing vitamin B12 deficiency-related fatigue or glossitis), Helicobacter pylori infection (associated with epigastric pain, early satiety, or halitosis), or autoimmune gastritis (which may manifest as pernicious anemia with macrocytic anemia, neuropathy, or cognitive changes). Iron-deficiency anemia may accompany FGPs in patients with concomitant erosive gastropathy, portal hypertensive gastropathy, or angiodysplasia—but FGPs themselves do not bleed or erode. Rarely, very large (>2 cm) or pedunculated FGPs may cause mechanical irritation, leading to transient, non-specific upper abdominal discomfort; however, such occurrences are exceptional and lack diagnostic specificity.

Complications: True complications directly attributable to FGPs are exceedingly rare. Malignant transformation is virtually nonexistent in sporadic FGPs—even with long-standing PPI use or large size. The estimated risk of dysplasia or carcinoma in sporadic FGPs is <0.1%, and when malignancy occurs, it is almost always in the context of FAP, where FGPs may harbor low-grade dysplasia (though progression to invasive cancer remains exceptionally uncommon). Other theoretical complications—including obstruction, intussusception, or acute gastric outlet obstruction—are not documented in the medical literature. Polyp-related hemorrhage does not occur because FGPs lack fragile vasculature or surface erosion; their epithelium remains intact and non-ulcerated. Importantly, FGPs do not predispose to gastric motility disorders, gastric volvulus, or perforation. The principal clinical concern lies not in complications of the polyps themselves, but in the implications of their presence: namely, the need to exclude FAP in patients with numerous (>20), large (>1 cm), or dysplastic FGPs—and to assess for concurrent gastric neoplasia (e.g., gastric adenocarcinoma) in patients with risk factors such as chronic atrophic gastritis or intestinal metaplasia.

Diagnosis methods: Diagnosis relies exclusively on upper gastrointestinal endoscopy with targeted biopsy and histopathological examination. Endoscopically, FGPs appear as multiple, small (typically 1–5 mm), smooth, sessile, translucent or pale-yellow polyps confined to the gastric fundus and body; they are usually uniform in size and lack central umbilication or surface irregularity. Chromoendoscopy (e.g., indigo carmine) may enhance visualization but is not required. Narrow-band imaging (NBI) often reveals a regular, honeycomb-like microsurface pattern consistent with non-neoplastic epithelium. Biopsy is mandatory for definitive diagnosis: histology shows dilated, cystically expanded fundic glands lined by mature parietal and chief cells without cytologic atypia, architectural distortion, or inflammatory infiltrate. Immunohistochemistry is rarely needed but may demonstrate strong H+/K+ ATPase expression in parietal cells. Serum gastrin measurement may support PPI-related etiology (mild-moderate elevation), but it is neither diagnostic nor clinically necessary. Genetic testing for APC gene mutations is indicated only in patients with >20 FGPs, young age at diagnosis (<40 years), personal/family history of colorectal neoplasia, or extracolonic FAP features (e.g., desmoid tumors, congenital hypertrophy of retinal pigment epithelium).

Differential diagnosis: Several gastric polypoid lesions must be distinguished from FGPs. Hyperplastic polyps—often larger, more proximal, and associated with chronic gastritis or H. pylori infection—exhibit foveolar hyperplasia, cystic dilation of surface glands, and inflammatory stroma; they carry a slightly increased risk of dysplasia, particularly if >1 cm or located in the antrum. Gastric adenomas (tubular, tubulovillous, or villous) display true dysplasia (architectural and cytologic abnormalities), are frequently solitary, and occur more commonly in the antrum; they confer a well-established risk of progression to adenocarcinoma. Hamartomatous polyps (e.g., Peutz-Jeghers or juvenile polyps) are rare in the stomach and exhibit distinctive stromal components (smooth muscle arborization or inflamed lamina propria). Neuroendocrine tumors (carcinoids) may mimic small polyps but demonstrate neuroendocrine differentiation on immunohistochemistry (chromogranin A, synaptophysin positivity) and may be associated with elevated serum chromogranin A or urinary 5-HIAA. Inflammatory fibroid polyps are submucosal, often pedunculated, and contain spindle cells admixed with eosinophils. Finally, metastatic lesions or lymphomas may rarely present as gastric polyps but are distinguished by clinical context, imaging, and deep biopsy. Accurate differentiation hinges on meticulous endoscopic characterization combined with systematic histopathologic evaluation—not clinical symptomatology, which is uniformly uninformative in this setting.

Fundic gland polyps (FGPs) are the most common gastric polyps encountered in clinical practice, typically discovered incidentally during upper gastrointestinal endoscopy. They arise from hyperplasia of the fundic gland mucosa—primarily parietal and chief cells—in the gastric fundus and body. FGPs are almost always benign, with an exceedingly low malignant potential (<0.1%), particularly in sporadic cases not associated with familial adenomatous polyposis (FAP). Management is therefore largely conservative and risk-stratified, guided by polyp size, number, morphology, histopathological features, and underlying clinical context.

Conservative treatment constitutes the cornerstone of management for the vast majority of patients. Sporadic FGPs smaller than 10 mm, solitary or few in number (≤5), and without dysplasia on biopsy require no intervention beyond surveillance. Current guidelines—including those from the American College of Gastroenterology (ACG) and the European Society of Gastrointestinal Endoscopy (ESGE)—recommend baseline endoscopic evaluation with high-definition white-light endoscopy (HD-WLE) and targeted biopsies to confirm histology and exclude dysplasia or coexisting lesions. For confirmed sporadic FGPs <10 mm without dysplasia, surveillance endoscopy is generally unnecessary unless new symptoms (e.g., epigastric pain, bleeding, anemia) emerge or polyp characteristics change. In contrast, patients with FAP-associated FGPs warrant lifelong surveillance due to increased gastric cancer risk, though even in this cohort, FGPs themselves rarely progress to malignancy; rather, attention focuses on detecting concomitant gastric adenomas or early gastric cancers.

Pharmacologic therapy has no established role in inducing regression or preventing recurrence of FGPs. Proton pump inhibitors (PPIs), widely used for acid-related disorders, have been epidemiologically linked to increased FGP prevalence—likely reflecting a reactive, non-neoplastic mucosal response to chronic acid suppression. However, discontinuation of PPIs does not reliably cause polyp regression, nor is it recommended solely for FGP management. There is no evidence supporting the use of aspirin, NSAIDs, COX-2 inhibitors, or chemopreventive agents for FGPs. Therefore, medication is not indicated for treatment but may be continued or adjusted based on underlying indications (e.g., GERD, peptic ulcer disease), with shared decision-making regarding long-term PPI use.

Surgical treatment is exceptionally rare and reserved only for highly selected scenarios. Endoscopic resection—specifically cold snare polypectomy (CSP) or, less commonly, hot snare polypectomy—is the standard intervention when therapeutic removal is warranted. Indications include: (1) polyps ≥10 mm (due to slightly elevated dysplasia risk and technical challenges in accurate biopsy sampling); (2) polyps with suspicious endoscopic features (e.g., nodularity, surface erosion, irregular margins); (3) histologically confirmed low-grade dysplasia (LGD), especially if incompletely sampled or recurrent; and (4) symptomatic polyps (e.g., causing chronic occult bleeding or obstruction). Endoscopic mucosal resection (EMR) may be employed for larger or flat lesions (>15 mm), while endoscopic submucosal dissection (ESD) is rarely needed and typically reserved for lesions with unequivocal high-grade dysplasia or early invasive carcinoma—conditions that are extraordinarily uncommon in true FGPs. Surgical gastrectomy has no role in isolated FGP management and would only be considered in the context of multifocal advanced neoplasia or invasive gastric cancer, which represents a distinct pathological process.

Treatment advantages in China reflect advances in endoscopic infrastructure, expertise, and integrated care models. Major tertiary hospitals—especially those affiliated with academic medical centers in Beijing, Shanghai, Guangzhou, and Chengdu—offer state-of-the-art endoscopic platforms including magnifying endoscopy with narrow-band imaging (ME-NBI), confocal laser endomicroscopy (pCLE), and AI-assisted real-time histology prediction, enabling highly accurate optical diagnosis and reducing unnecessary biopsies. Endoscopists in China undergo rigorous standardized training through the Chinese Society of Gastrointestinal Endoscopy (CSGE), with high procedural volumes ensuring proficiency in CSP and EMR. Furthermore, China’s national endoscopic quality improvement initiatives emphasize complete resection rates, retrieval efficiency, and histopathological correlation—critical for reliable FGP characterization. Cost-effectiveness is another advantage: endoscopic resection in China is significantly more affordable than in Western countries, with minimal out-of-pocket expense for insured patients under the National Basic Medical Insurance scheme. Importantly, multidisciplinary tumor boards routinely review complex gastric polyp cases, facilitating timely referral to surgical oncology or genetics services when FAP or hereditary syndromes are suspected.

Recovery following endoscopic resection of FGPs is typically rapid and uncomplicated. Patients are advised to resume clear liquids 2–4 hours post-procedure and advance to soft, bland foods within 24 hours. A 3–5 day course of proton pump inhibitor therapy (e.g., esomeprazole 40 mg daily) is recommended to promote mucosal healing and reduce post-polypectomy bleeding risk—even in asymptomatic individuals. Heavy lifting, vigorous exercise, and NSAID use should be avoided for 7 days. Most patients return to normal activities within 48–72 hours. Follow-up endoscopy is individualized: for completely resected, non-dysplastic FGPs ≥10 mm, repeat examination in 12 months is reasonable to assess for recurrence or metachronous lesions; however, recurrence rates are low (<5% at 3 years), and long-term surveillance intervals can be extended in stable patients. Lifestyle counseling emphasizes balanced nutrition, smoking cessation, and moderation of alcohol intake—not because these directly affect FGPs, but as part of holistic gastric health maintenance. Patients with newly diagnosed FAP require coordinated genetic counseling, annual upper endoscopy starting at age 20–25, and consideration of prophylactic colectomy per international guidelines. Finally, all patients should be educated that FGPs are overwhelmingly benign and that anxiety about malignancy is rarely warranted—emphasizing evidence-based reassurance over routine intervention.